Navigation Links
Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
Date:7/1/2009

ly member, may have. Inform the doctor immediately if you or your child develops symptoms that suggest heart problems, such as chest pain or fainting.

Vyvanse should not be taken if you or your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking Vyvanse if you or your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if you or your child develops any of these conditions or symptoms while taking Vyvanse.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

Talk to your health care provider if your child experiences slowing of growth (height and weight). Children should have their height and weight checked periodically while taking Vyvanse. Your health care provider may stop Vyvanse treatment if a problem is found during these check-ups.

Vyvanse was generally well tolerated in clinical studies. The most common side effects reported in studies of Vyvanse were: children - decreased appetite, difficulty falling asleep, stomachache, and irritability; adult
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
2. Yaupon Therapeutics Completes Patient Enrollment for Pivotal Phase 2 Study of Clearazide for Treatment of Cutaneous T-cell Lymphoma
3. SRNL to study applicability of solar cell coatings
4. Elsevier Releases Results of Alternative Energy Research Leadership Study Identifying Top 25 Institutions Worldwide
5. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
6. New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery
7. Advanced Life Sciences Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study
8. Springborn Deploys eStudy(TM) Hosted Solution for Management of Global Environmental Testing
9. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
10. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
11. Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,, REYKJAVIK,Iceland,November24/PRNewswire-F...yannouncedtheapprovalofallofits,"firstday"motionsb...he"BankruptcyCourt").deCODElastweekfiledavoluntary...ankruptcyCodewiththe,BankruptcyCourt. , Theor...tinue,tooperateitsbusinessduringtheChapter11procee...
(Date:11/24/2009)...,, SEATTLE,Nov.24/PRNewswire/--BlueMarbleEne...blicDevelopmentAuthority(OPDA)wererecentlyawarded$...lizationBoard(CERB)inaprivate/publicpartnershiptoc...neryinLincolnCounty,WA. ,, "Thisinvestmentwills...bringover70greenjobstoLincolnCounty,"saidBlueMarbl...
(Date:11/24/2009)...,, DUBLIN,November24/PRNewswire-FirstCall/--...tybiopharmaceuticalcompany,today,announcedthatitha...glucerasealfa,thecompany,senzymereplacementtherapy....Thisisthethirdmarketing,applicationforvelaglucera...sintheUnitedStatesandCanada. , Basedonaglobal...
(Date:11/24/2009)..., Program Connects Custom... Samples Collected with DNA Genotek Products , ...24, 2009 -- DNA Genotek , a leading provider of p...ation and preparation, today announced its new glo...t enhancements for DNA Genotek,s partner community...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ons has,long been used as a marketing tool by the ...bility to reach consumers has never been greater. ...joined the traditional press,release as effective ...his,understanding, new research was conducted by B...ns activities are most effective at educating,and ...
...ytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announ...nterim results of a U.S. Phase II trial investigat...and soft tissue sarcomas metastatic to,the lung is...nstitute of,Drug Development (IDD), the Cancer The...s Health Science Center, (UTHSC), San Antonio, Tex...
...d its annual "Power of Partnership" award to Baxte...cal device and specialty pharmaceutical,company. B...ibution,Management Association,s (HDMA) Annual Lea...Power of Partnership" award was created by AmeriCa...d distribution organizations that have,shown excep...
Other Biology Technology:New Study Shares Best Practices in Biopharma Public Relations 2Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data 2Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data 3AmeriCares Presents 'Power of Partnership' Award to Baxter 2AmeriCares Presents 'Power of Partnership' Award to Baxter 3
(Date:11/26/2009)... Aureus ) and other drug-resistant bacteria could ...ype devices have been developed to offer safe, qui... Two prototype devices have been developed: one fo...ds and feet) in hospitals and public spaces where ...shoot bacteria-killing agents into infested chroni...
(Date:11/25/2009)...ers and ambulance workers faced a terrifying rescu...attled to save people from the collapsing Twin Tow...cuated as many people as they could in an area whi...g their jobs even harder was the problem of poor c...ves jammed mobile networks with calls and the emer...
(Date:11/25/2009)...ors recently received funding from the National Sc...cial to understanding the environment. The three g...ssistant professor in the Department of Biological...ate research projects. , His first project, titl...unctions from the Leaf to the Landscape," will exa...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Magic box for mission impossible 2Magic box for mission impossible 3Kent State University professors focus research on the environment with grants totaling $890,000 2Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 1Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 2Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 3Bonus Payout Trends and Continuing Cost Controls Reflect Challenging Business Climate Says Aon Consultings Radford 48659 4Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 1Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 2Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 3Actuaries Weigh in on Ways to Address Risk Exposures and Challenges with the U S Health Care System 48656 4Cornflakes White Bread Could Boost Heart Risk 48653 1Cornflakes White Bread Could Boost Heart Risk 48653 2Cornflakes White Bread Could Boost Heart Risk 48653 3
...ook For Biometrics Revenue and Profit Growth, WAL...Bulletin Board: BKYI), a leader in wireless public...solutions, today announced its,financial results f...tal revenue from continuing operations for the thr...n representing a 27% decrease from the,$3.0 millio...
...a. --- The observation that males evolve more quic...y biologist Charles Darwin noted the majesty of a ...ness of the peahens. , No matter the species, mal...elodious warbles in an eternal competition to win ...n. , Why males are in evolutionary overdrive even...
...s prepare to discuss conservation-friendly carbon ...s a new wave of deforestation in the South America...t Anglia and Brazils Goeldi Museum highlights once...n forest. , Working in the north-eastern Brazili...ertook the single-largest assessment of the biodiv...
Other Biology News:BIO-key Reports Third Quarter 2007 Results 2BIO-key Reports Third Quarter 2007 Results 3BIO-key Reports Third Quarter 2007 Results 4BIO-key Reports Third Quarter 2007 Results 5Simple reason helps males evolve more quickly 2Simple reason helps males evolve more quickly 3Single-largest biodiversity survey says primary rainforest is irreplaceable 2
Expansion and Cryopreservation of Cells from Meridian Life Science, Inc.
HandyStep manual repeating pipette from BrandTech Scientific
Zymo-Spin I-96 from Zymo Research
RT-PCR Grade Water from Ambion
Biology Products: